[{"id":"79754c99-3751-46a3-9cbb-21442fd0c3e5","acronym":"NRG-GY023","url":"https://clinicaltrials.gov/study/NCT04739800","created_at":"2021-02-05T13:56:26.400Z","updated_at":"2025-02-25T15:26:41.757Z","phase":"Phase 2","brief_title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","source_id_and_acronym":"NCT04739800 - NRG-GY023","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/10/2021","start_date":" 06/10/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"caa0f388-4c19-438d-9bce-36b37f87c82f","acronym":"NRG-GY004","url":"https://clinicaltrials.gov/study/NCT02446600","created_at":"2021-01-18T11:43:37.532Z","updated_at":"2025-02-25T15:06:35.061Z","phase":"Phase 3","brief_title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02446600 - NRG-GY004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 579","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 02/23/2020","primary_completion_date":" 02/23/2020","study_txt":" Completion: 08/23/2025","study_completion_date":" 08/23/2025","last_update_posted":"2025-02-03"},{"id":"66e980f4-fc20-4c1f-b295-732ba31ba490","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345265","created_at":"2021-01-18T11:09:11.903Z","updated_at":"2025-02-25T17:29:14.435Z","phase":"Phase 2","brief_title":"Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02345265","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/23/2016","start_date":" 05/23/2016","primary_txt":" Primary completion: 07/07/2022","primary_completion_date":" 07/07/2022","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2025-01-30"},{"id":"eccae38b-1886-4206-b6f1-ab2c523e9706","acronym":"BAROCCO","url":"https://clinicaltrials.gov/study/NCT03314740","created_at":"2021-01-18T16:22:11.917Z","updated_at":"2025-02-25T14:58:26.251Z","phase":"Phase 2","brief_title":"Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib","source_id_and_acronym":"NCT03314740 - BAROCCO","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 06/12/2017","start_date":" 06/12/2017","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2025-01-10"},{"id":"4f33daa7-3ce5-4186-b28f-85f4758b6b4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01116648","created_at":"2021-01-18T04:25:31.641Z","updated_at":"2025-02-25T16:23:24.150Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01116648","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 04/14/2010","start_date":" 04/14/2010","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 02/13/2025","study_completion_date":" 02/13/2025","last_update_posted":"2024-10-31"},{"id":"2386852e-1c2a-4d97-ae6c-dd2f1c49a6e0","acronym":"NCI-2015-01097","url":"https://clinicaltrials.gov/study/NCT02498613","created_at":"2021-01-18T12:02:57.557Z","updated_at":"2025-02-25T15:06:40.982Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","source_id_and_acronym":"NCT02498613 - NCI-2015-01097","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression • ALK mutation","tags":["EGFR • HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 06/22/2022","primary_completion_date":" 06/22/2022","study_txt":" Completion: 04/10/2025","study_completion_date":" 04/10/2025","last_update_posted":"2024-09-26"},{"id":"e0d150b0-e8da-41e4-9df7-1fc41df6dcb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02484404","created_at":"2021-01-17T17:57:31.886Z","updated_at":"2024-07-02T16:34:36.994Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","source_id_and_acronym":"NCT02484404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation","tags":["EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 384","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-06-07"},{"id":"4c69c646-417d-429d-bb95-ea9731d61b06","acronym":"COCOS","url":"https://clinicaltrials.gov/study/NCT02502266","created_at":"2021-01-18T12:04:33.243Z","updated_at":"2024-07-02T16:35:02.420Z","phase":"Phase 2/3","brief_title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT02502266 - COCOS","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 562","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-21"},{"id":"f6e94490-8464-4ca1-871d-9dfc5c85f532","acronym":"DAPPER","url":"https://clinicaltrials.gov/study/NCT03851614","created_at":"2021-01-18T19:00:33.382Z","updated_at":"2025-02-25T15:08:21.640Z","phase":"Phase 2","brief_title":"Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03851614 - DAPPER","lead_sponsor":"University Health Network, Toronto","biomarkers":" HRD • CD4","pipe":"","alterations":" ","tags":["HRD • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 04/08/2019","start_date":" 04/08/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-15"},{"id":"06d625a6-cf6f-4d0a-9c63-1adbf21e5730","acronym":"","url":"https://clinicaltrials.gov/study/NCT01364051","created_at":"2024-03-13T08:33:16.360Z","updated_at":"2024-07-02T16:35:15.340Z","phase":"Phase 1","brief_title":"Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies","source_id_and_acronym":"NCT01364051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 05/25/2011","start_date":" 05/25/2011","primary_txt":" Primary completion: 06/06/2019","primary_completion_date":" 06/06/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"86171696-4f6d-47df-9ec6-eddd532805f3","acronym":"NCI-2019-04148","url":"https://clinicaltrials.gov/study/NCT04090567","created_at":"2021-01-18T20:01:10.424Z","updated_at":"2024-07-02T16:35:22.234Z","phase":"Phase 2","brief_title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","source_id_and_acronym":"NCT04090567 - NCI-2019-04148","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • BRCA","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-01-25"},{"id":"a892c189-b7f0-4c8f-8416-82e738f881bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00107250","created_at":"2021-01-18T00:20:58.610Z","updated_at":"2024-07-02T16:35:41.026Z","phase":"Phase 1","brief_title":"AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)","source_id_and_acronym":"NCT00107250","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • capecitabine • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 01/21/2005","start_date":" 01/21/2005","primary_txt":" Primary completion: 10/23/2009","primary_completion_date":" 10/23/2009","study_txt":" Completion: 01/18/2011","study_completion_date":" 01/18/2011","last_update_posted":"2023-08-04"},{"id":"e3be1966-6c30-4f06-953e-aff97254829b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00343408","created_at":"2021-01-18T01:11:14.135Z","updated_at":"2024-07-02T16:35:40.898Z","phase":"Phase 1","brief_title":"AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer","source_id_and_acronym":"NCT00343408","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/29/2005","start_date":" 11/29/2005","primary_txt":" Primary completion: 09/18/2007","primary_completion_date":" 09/18/2007","study_txt":" Completion: 09/22/2008","study_completion_date":" 09/22/2008","last_update_posted":"2023-08-04"},{"id":"f1ea7b96-a957-4ae1-8fe0-ece991ec008e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00245154","created_at":"2021-01-18T00:49:53.635Z","updated_at":"2024-07-02T16:35:40.977Z","phase":"Phase 2/3","brief_title":"Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00245154","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 296","initiation":"Initiation: 11/03/2005","start_date":" 11/03/2005","primary_txt":" Primary completion: 07/04/2008","primary_completion_date":" 07/04/2008","study_txt":" Completion: 01/10/2013","study_completion_date":" 01/10/2013","last_update_posted":"2023-08-04"},{"id":"2c6224b1-6f93-44a7-ab06-1118d56ce71d","acronym":"WIRE","url":"https://clinicaltrials.gov/study/NCT03741426","created_at":"2021-01-18T18:19:37.462Z","updated_at":"2025-02-25T15:08:06.815Z","phase":"Phase 2","brief_title":"WIRE - Novel Treatments in Renal Cell Cancer","source_id_and_acronym":"NCT03741426 - WIRE","lead_sponsor":"CCTU- Cancer Theme","biomarkers":" CD8 • IL2","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2023-06-07"},{"id":"d73b7d49-07e5-44d5-ad25-1092c7461f92","acronym":"ICON9","url":"https://clinicaltrials.gov/study/NCT03278717","created_at":"2021-01-18T16:11:26.978Z","updated_at":"2024-07-02T16:36:03.424Z","phase":"Phase 3","brief_title":"Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients","source_id_and_acronym":"NCT03278717 - ICON9","lead_sponsor":"University College, London","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation • MUC16 elevation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 06/15/2018","start_date":" 06/15/2018","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-09-27"},{"id":"f4c7c20e-d259-4ffc-bb7c-180cf66db5b1","acronym":"CONCERTO","url":"https://clinicaltrials.gov/study/NCT02889900","created_at":"2021-01-18T14:10:59.140Z","updated_at":"2025-02-25T16:05:10.639Z","phase":"Phase 2b","brief_title":"Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT02889900 - CONCERTO","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 01/17/2017","start_date":" 01/17/2017","primary_txt":" Primary completion: 08/27/2019","primary_completion_date":" 08/27/2019","study_txt":" Completion: 03/16/2021","study_completion_date":" 03/16/2021","last_update_posted":"2022-03-08"},{"id":"0aeeb130-65a0-4509-a82f-f4648e288552","acronym":"MOLTO","url":"https://clinicaltrials.gov/study/NCT02855697","created_at":"2021-01-18T14:00:56.663Z","updated_at":"2024-07-02T16:36:16.827Z","phase":"Phase 1","brief_title":"Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT02855697 - MOLTO","lead_sponsor":"The Christie NHS Foundation Trust","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 05/26/2017","start_date":" 05/26/2017","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-02-22"},{"id":"868f20e2-cb59-435e-8f2a-4edb23b8dd9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01208051","created_at":"2021-01-18T04:50:33.670Z","updated_at":"2024-07-02T16:36:27.878Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01208051","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAS • TG","pipe":" | ","alterations":" RAS mutation","tags":["BRAF • RAS • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 09/09/2010","start_date":" 09/09/2010","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2021-07-15"},{"id":"76b17540-6ece-430c-b9e2-02d3931d1cde","acronym":"COMICE","url":"https://clinicaltrials.gov/study/NCT04487587","created_at":"2021-01-18T21:32:30.911Z","updated_at":"2024-07-02T16:36:42.745Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer","source_id_and_acronym":"NCT04487587 - COMICE","lead_sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 10/09/2018","start_date":" 10/09/2018","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2020-07-27"},{"id":"18355d3c-f7e1-448b-ab4c-11229b808bb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00278343","created_at":"2021-01-18T00:56:52.905Z","updated_at":"2024-07-02T16:37:07.384Z","phase":"Phase 2","brief_title":"Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer","source_id_and_acronym":"NCT00278343","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 06/01/2010","primary_completion_date":" 06/01/2010","study_txt":" Completion: 01/15/2018","study_completion_date":" 01/15/2018","last_update_posted":"2018-08-29"},{"id":"268100a2-42e8-4e0c-a769-0efa32ad295d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02340611","created_at":"2021-01-18T11:07:19.601Z","updated_at":"2025-02-25T15:06:26.713Z","phase":"Phase 2","brief_title":"A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib","source_id_and_acronym":"NCT02340611","lead_sponsor":"University Health Network, Toronto","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-06-12"},{"id":"d4028889-e16a-46e8-97f5-4a889143bec1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00243074","created_at":"2021-01-18T00:49:18.168Z","updated_at":"2024-07-02T16:37:14.644Z","phase":"Phase 2","brief_title":"S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00243074","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KDR","pipe":"","alterations":" ","tags":["KDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Recentin (cediranib)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 11/01/2005","start_date":" 11/01/2005","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2018-01-23"}]